gc203
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2023 (NCT06488950)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07256756 | Phase 1 | Nov 30, 2025 | Government of China, Southern Medical University |
| NCT06828328 | Early Phase 1 (Phase 1) | Feb 10, 2025 | Government of China |
| NCT06488950 | Early Phase 1 (Phase 1) | Apr 1, 2023 | Eastern Hepatobiliary Surgery Hospital, Government of China |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 1 | 2023 |
| Eastern Hepatobiliary Surgery Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1